ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,821Medicare Part D Prescriptions Filled, Including Refills

Rank: 360 out of 1121

$449K Total Retail Price of All Prescriptions

Rank: 469 out of 1121

426 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Tennessee
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 426 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

13% of this provider’s 426 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

3% of this provider’s 8,418 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Tennessee
AMLODIPINE BESYLATE 464 425 1 5
SIMVASTATIN 452 423 2 1
LEVOTHYROXINE SODIUM 413 370 3 2
LISINOPRIL 337 313 4 4
OMEPRAZOLE 336 301 5 6
HYDROCODONE-ACETAMINOPHEN 329 224 S3 6 3
ATENOLOL 299 252 7 16
SERTRALINE HCL 230 202 8 21
FUROSEMIDE 224 214 9 7
WARFARIN SODIUM 218 167 10 11
AZITHROMYCIN 167 138 11 44
TRAZODONE HCL 163 146 12 40
METFORMIN HCL 157 136 13 8
ATORVASTATIN CALCIUM 145 132 14 15
POTASSIUM CHLORIDE 125 111 15 12
TRIAMTERENE-HCTZ 124 88 16 38
MELOXICAM 116 104 17 22
METOPROLOL SUCCINATE 110 102 18 23
GABAPENTIN 105 85 19 13
LOVASTATIN 104 92 20 26
CITALOPRAM HBR 103 90 21 18
METFORMIN HCL ER 96 91 22 47
GLYBURIDE MICRONIZED 94 93 R 23 258
NEXIUM 93 76 24 24
ZOLPIDEM TARTRATE 86 52 25 19
TRAMADOL HCL 82 82 26 25
DIOVAN 81 77 27 45
METOPROLOL TARTRATE 79 75 28 9
VERAPAMIL ER 75 75 29 89
CLOPIDOGREL 73 73 30 27
JANUVIA 66 57 31 81
MECLIZINE HCL 65 65 32 115
VENTOLIN HFA 65 63 32 92
ALLOPURINOL 64 52 34 30
ENALAPRIL MALEATE 60 54 35 73
CLONIDINE HCL 59 59 36 39
FAMOTIDINE 58 53 37 63
PLAVIX 57 57 38 42
FENTANYL 57 21 S2 38 100
PANTOPRAZOLE SODIUM 56 49 40 29
CIPROFLOXACIN HCL 56 46 40 57
AMOX TR-POTASSIUM CLAVULANATE 53 45 42 101
CELEBREX 52 35 43 104
TAMSULOSIN HCL 51 51 44 32
POLYETHYLENE GLYCOL 3350 51 40 44 70
FLUOXETINE HCL 51 39 44 60
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 23, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.